Table 2 Associations between clinicopathologic factors and density of CD8(+) T cells and programmed cell death-1 (PD-1) expression on CD8(+) T cells in primary tumors and lymph nodes of gastric adenocarcinoma
Variable | Total (cases) | Density of CD8(+) T cells in primary tumors [cases (%)] | PD-1 expression on CD8(+) T cells [cases (%)] | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Primary tumors | Metastatic lymph nodes | Tumor-free lymph nodes | |||||||||||
Low | High | P | Negative | Positive | P | Negative | Positive | P | Negative | Positive | P | ||
Total | 119 | 46 | 73 | Â | 74 | 45 | Â | 72 | 47 | Â | 106 | 13 | Â |
Sex | Â | Â | Â | 0.263 | Â | Â | 0.155 | Â | Â | 0.434 | Â | Â | 0.982 |
 Male | 78 | 33 (42.3) | 45 (57.7) |  | 45 (57.7) | 33 (42.9) |  | 45 (57.7) | 33 (42.3) |  | 69 (88.5) | 9 (11.5) |  |
 Female | 41 | 13 (31.7) | 28 (68.3) |  | 29 (70.7) | 12 (29.3) |  | 27 (65.9) | 14 (34.1) |  | 37 (90.2) | 4 (9.8) |  |
Age (years) | Â | Â | Â | 0.631 | Â | Â | 0.940 | Â | Â | 0.852 | Â | Â | 0.934 |
 <55 | 55 | 20 (36.4) | 35 (63.6) |  | 34 (61.8) | 21 (38.2) |  | 34 (61.8) | 21 (38.2) |  | 49 (89.1) | 6 (10.9) |  |
 ≥55 | 64 | 26 (40.6) | 38 (59.4) |  | 40 (62.5) | 24 (37.5) |  | 38 (59.4) | 26 (40.6) |  | 57 (89.1) | 7 (10.9) |  |
Tumor location | Â | Â | Â | 0.782 | Â | Â | 0.464 | Â | Â | 0.552 | Â | Â | 0.648 |
 Cardia | 49 | 19 (38.8) | 30 (61.2) |  | 32 (65.3) | 17 (34.7) |  | 30 (61.2) | 19 (38.8) |  | 43 (87.8) | 6 (12.2) |  |
 Body | 20 | 9 (45.0) | 11 (55.0) |  | 10 (50.0) | 10 (50.0) |  | 10 (50.0) | 10 (50.0) |  | 17 (85.0) | 3 (15.0) |  |
 Antrum | 50 | 18 (36.0) | 32 (64.0) |  | 32 (64.0) | 18 (36.0) |  | 32 (64.0) | 18 (36.0) |  | 46 (92.0) | 4 (8.0) |  |
Cell differentiation | Â | Â | Â | 0.660 | Â | Â | 0.981 | Â | Â | 0.799 | Â | Â | 0.906 |
 Well to moderate | 21 | 9 (42.9) | 12 (57.1) |  | 13 (61.9) | 8 (38.1) |  | 12 (57.1) | 9 (42.9) |  | 20 (95.2) | 1 (4.8) |  |
 Poor (including Signet ring cell) | 98 | 37 (37.8) | 61 (62.2) |  | 61 (62.2) | 37 (37.8) |  | 60 (61.2) | 38 (38.8) |  | 86 (87.8) | 12(12.2) |  |
Lauren classification | Â | Â | Â | 0.011 | Â | Â | 0.103 | Â | Â | 0.061 | Â | Â | 0.239 |
 Intestinal | 60 | 30 (50.0) | 30 (50.0) |  | 33 (55.0) | 27 (45.0) |  | 31 (51.7) | 29 (48.3) |  | 51 (85.0) | 9 (15.0) |  |
 Diffuse and mixed | 59 | 16 (27.1) | 43 (72.9) |  | 41 (69.5) | 18 (30.5) |  | 41 (69.5) | 18 (30.5) |  | 55 (93.2) | 4 (6.8) |  |
Vascular invasion | Â | Â | Â | 0.302 | Â | Â | 0.114 | Â | Â | 0.454 | Â | Â | 0.572 |
 Yes | 55 | 24 (43.6) | 31 (56.4) |  | 30 (54.5) | 25 (45.5) |  | 41 (64.1) | 23 (35.9) |  | 58 (90.6) | 6 (9.4) |  |
 No | 64 | 22 (34.4) | 42 (65.6) |  | 44 (68.8) | 20 (31.3) |  | 31 (56.4) | 24 (43.6) |  | 48 (87.3) | 7 (12.7) |  |
Neural invasion | Â | Â | Â | 0.488 | Â | Â | 0.457 | Â | Â | 0.433 | Â | Â | 0.951 |
 Yes | 77 | 28 (36.4) | 49 (63.6) |  | 46 (59.7) | 31 (40.3) |  | 23 (54.8) | 19 (45.2) |  | 38 (90.5) | 4 (9.5) |  |
 No | 42 | 18 (42.9) | 24 (57.1) |  | 28 (66.7) | 14 (33.3) |  | 49 (53.6) | 28 (36.4) |  | 68 (88.3) | 9 (11.7) |  |
Clinical stage | Â | Â | Â | 0.018 | Â | Â | 0.113 | Â | Â | 0.122 | Â | Â | 0.357 |
 II–IIIA | 12 | 1 (8.3) | 11 (91.7) |  | 10 (83.3) | 2 (16.7) |  | 10 (83.3) | 2 (16.7) |  | 11 (91.7) | 1 (8.3) |  |
 IIIB–IIIC | 107 | 45 (42.1) | 62 (57.9) |  | 64 (59.8) | 43 (40.2) |  | 62 (57.9) | 45 (42.1) |  | 95 (88.8) | 12 (11.2) |  |